Sanofi's Board of Directors notes the resignation of Christian Mulliez and co-opts Christophe Babule as Director
06 Febrero 2019 - 3:00PM
|
Press Release
Source: Sanofi (EURONEXT: SAN) (NASDAQ: SNY)
|
Sanofi's Board of Directors notes the resignation
of Christian Mulliez and co-opts Christophe Babule as
Director
-
Notes the resignation of Christian Mulliez as of
February 6, 2019
-
Co-opts Christophe Babule for the remainder of
Christian Mulliez's term of office
PARIS - February 6, 2019 - At its meeting held
on February 6, 2019, the Board of Directors duly noted the
resignation of Mr. Mulliez and decided, after consultation of the
Appointments and Governance Committee, to co-opt Christophe Babule
as Director for the remainder of Christian Mulliez's term of office
(expiring at the end of the Annual Shareholders' Meeting held in
2022 to approve the financial statements for the fiscal year ending
December 31, 2021).
The co-optation of Christophe
Babule will be subject to ratification by the next Shareholders'
Meeting of Sanofi, on April 30, 2019.
On November 19, 2018 Christophe
Babule has been appointed Executive Vice-President, Chief Financial
Officer and member of L'Oréal's Executive Committee as of
mid-February 2019. Christophe Babule has spent his career with
L'Oréal, which he joined in 1988 after his studies at HEC Paris. He
spent 7 years in the Luxury Division in Italy before being
appointed as Director of Administration & Finance based in
China. In 2007, he was appointed Administration & Financial
Director for Mexico. In 2010, he returned to France to join
Christian Mulliez's Executive Committee as Director of Internal
Audit for nearly 5 years. Afterwards he was appointed to his
current position as Administration & Financial Director for the
Asia Pacific Zone based in Shanghai and then in Hong Kong.
In making this appointment, the
Board of Directors has chosen an individual with recognized skills
in high-priority areas for the Group while maintaining the current
balance of competences, in accordance with the roadmap set by the
Board relative to its composition.
The entire Board of Directors
thanked Christian Mulliez, who was also member of the Audit
Committee and the Compensation Committee, for his very substantial
and active participation in the meetings of the Board and of its
Committees.
The Board of Directors has 16
members, including 11 who are deemed independent and two Directors
representing employees.
About Sanofi
Sanofi is dedicated to supporting people through their health
challenges. We are a global biopharmaceutical company focused on
human health. We prevent illness with vaccines, provide innovative
treatments to fight pain and ease suffering. We stand by the few
who suffer from rare diseases and the millions with long-term
chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is
transforming scientific innovation into healthcare solutions around
the globe.
Sanofi, Empowering Life
|
Media Relations Contact Quentin
Vivant
Tel.: +33 (0)1 53 77 41 09
Quentin.Vivant@sanofi.com
|
Investor Relations Contact George
Grofik
Tel.: +33 (0)1 53 77 45 45
ir@sanofi.com
|
|
About
Sanofi
Sanofi is dedicated to supporting
people through their health challenges. We are a global
biopharmaceutical company focused on human health. We prevent
illness with vaccines, provide innovative treatments to fight pain
and ease suffering. We stand by the few who suffer from rare
Press release (PDF)
This
announcement is distributed by West Corporation on behalf of West
Corporation clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Sanofi via Globenewswire
Sanofi (EU:SAN)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Sanofi (EU:SAN)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024